Greg Freitag

Joined AIAIA Board: 2026

Education:

  • Greg earned his BA in Business & Economics at Macalester College and his J.D. Law at the University of Chicago

Career Summary:

  •  Greg currently serves as a member of the Board of Directors of PDS Biotechnology Company (NASDAQ: PDSB), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and ZyVersa Therapeutics (Nasdaq: ZVSA), a clinical-stage specialty biopharmaceutical company developing drugs to treat inflammatory and renal diseases.

  • Prior to his retirement in April 2021 held various executive position with Axogen, Inc. (Nasdaq: AXGN), including General Counsel, Chief Financial Officer, and Senior Vice President of Business Development.  Mr. Freitag was also a member of the Axogen, Inc. Board of Directors from 2011 to 2024.  Axogen, Inc. is a leading regenerative medicine company dedicated to peripheral nerve repair.

  • Greg was Chief Executive Officer, Chief Financial Officer and a Board member from June 2010 through September 2011 of LecTec Corporation, an intellectual property licensing and holding company that merged with Axogen in September 2011.

  • Greg started his career practicing corporate law in Minneapolis and has served on a number of for-profit Boards of Directors and was previously on the Board of Directors of People Serving People, a family homeless shelter and the HealthEast Care System Foundation Board.

Why you’re proud to be a Board Member of Arm in Arm:

  • Greg, and his wife, Shari, are no strangers to Arm in Arm. They made their first visit to SA in 2019 and spent a day with Spiwo immersing themselves in the work of Arm in Arm. They returned home and became donors and introduced Arm in Arm to Arlene Bennett, Greg’s mother. Upon her passing, Arlene’s estate left Arm in Arm more than $160,000, the single largest gift in the organization’s history.

  • Greg & Shari are also delegates on the 2026 delegation.